Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Feb;35(2):114–120. doi: 10.1111/j.1365-2125.1993.tb05676.x

CNS-related performance and haemodynamics of metoprolol-Oros and propranolol after single and 3 days dosing in healthy volunteers.

A L van Steveninck 1, M S Pieters 1, H C Schoemaker 1, D D Breimer 1, A F Cohen 1
PMCID: PMC1381501  PMID: 8443028

Abstract

1. The effects of metoprolol-Oros 14/190 once daily, propranolol 80 mg twice daily and temazepam 10 mg once daily on central nervous system (CNS) related performance and haemodynamic variables were evaluated in a double-blind, randomized, placebo controlled, crossover study in 12 healthy volunteers. Drugs were administered for 3 consecutive days except for temazepam, which was administered on days 1 and 3 only. Treatment effects were evaluated at 0, 2, 5 and 8 h on days 1 and 3. 2. Neither beta-adrenoceptor blocker had significant effects in a battery of tests after single or 3 days dosing. Temazepam caused a decrease in saccadic peak velocity of 37.4 degrees s-1 (95% CI: 6.0, 68.9) at 2 h and an increase of auditory reaction times of 11.5 ms (0.2, 22.8) at 8 h on day 1. No significant effects of temazepam were detected on day 3. 3. Both beta-adrenoceptor blockers reduced exercise heart rate. Peak effects were measured at 2 h 40 min after propranolol but not metoprolol-Oros (difference, day 1:20 (11, 29) beats min-1, day 3:13 (8, 19) beats min-1). Both beta-adrenoceptor blockers significantly reduced baseline exercise heart rate on day 3. Compared with day 1, metoprolol-Oros caused larger reductions of exercise heart rate at all times on day 3. 4. Metoprolol-Oros and propranolol caused similar reductions of systolic- and diastolic blood pressure on days 1 and 3. Temazepam caused a small reduction in diastolic blood pressure at 5 h 40 min on day 1 but was otherwise devoid of haemodynamic effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
114

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benfield P., Clissold S. P., Brogden R. N. Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs. 1986 May;31(5):376–429. doi: 10.2165/00003495-198631050-00002. [DOI] [PubMed] [Google Scholar]
  2. Carruthers G., Shearer R., Taylor W., Moore M. A comparison of a controlled release (CR/ZOK) formulation of metoprolol, once daily, with conventional metoprolol tablets, twice daily, in mild to moderate hypertension. J Clin Pharmacol. 1990 Feb;30(2 Suppl):S61–S65. doi: 10.1002/j.1552-4604.1990.tb03498.x. [DOI] [PubMed] [Google Scholar]
  3. Dimenäs E. S., Dahlöf C. G., Heibel B., Moore R. G., Olofsson B. K., Westergren G. E., Lücker P. W. Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol. Eur J Clin Pharmacol. 1990;38(6):571–578. doi: 10.1007/BF00278584. [DOI] [PubMed] [Google Scholar]
  4. Dimenäs E., Dahlöf C., Olofsson B., Wiklund I. CNS-related subjective symptoms during treatment with beta 1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies. Br J Clin Pharmacol. 1989 Nov;28(5):527–534. doi: 10.1111/j.1365-2125.1989.tb03538.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dimenäs E., Dahlöf C. Tolerability and well-being with metoprolol in a controlled release (CR/ZOK) formulation: a review article. J Clin Pharmacol. 1990 Feb;30(2 Suppl):S92–S97. doi: 10.1002/j.1552-4604.1990.tb03504.x. [DOI] [PubMed] [Google Scholar]
  6. Dimenäs E., Ostergren J., Lindvall K., Dahlöf C., Westergren G., de Faire U. Comparison of CNS-related subjective symptoms in hypertensive patients treated with either a new controlled release (CR/ZOK) formulation of metoprolol or atenolol. J Clin Pharmacol. 1990 Feb;30(2 Suppl):S82–S90. doi: 10.1002/j.1552-4604.1990.tb03502.x. [DOI] [PubMed] [Google Scholar]
  7. Dimsdale J. E., Newton R. P., Joist T. Neuropsychological side effects of beta-blockers. Arch Intern Med. 1989 Mar;149(3):514–525. [PubMed] [Google Scholar]
  8. Feliciano N. R., Bouvet A. A., Redalieu E., Castellana J., Luders R. C., Schwartz D. J., Shum L., Zak S., Arnold J. D., Leese P. T. Pharmacokinetic and pharmacodynamic comparison of an osmotic release oral metoprolol tablet and the metoprolol conventional tablet. Am Heart J. 1990 Aug;120(2):483–489. doi: 10.1016/0002-8703(90)90109-b. [DOI] [PubMed] [Google Scholar]
  9. Houtzagers J. J., Smilde J. G., Creytens G., Westergren G. Efficacy and tolerability of a new controlled-release formulation of metoprolol: a comparison with conventional metoprolol tablets in mild to moderate hypertension. Eur J Clin Pharmacol. 1988;33 (Suppl):S39–S44. doi: 10.1007/BF00578411. [DOI] [PubMed] [Google Scholar]
  10. Israili Z. H. Correlation of pharmacological effects with plasma levels of antihypertensive drugs in man. Annu Rev Pharmacol Toxicol. 1979;19:25–52. doi: 10.1146/annurev.pa.19.040179.000325. [DOI] [PubMed] [Google Scholar]
  11. Kostis J. B., Rosen R. C. Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties. Circulation. 1987 Jan;75(1):204–212. doi: 10.1161/01.cir.75.1.204. [DOI] [PubMed] [Google Scholar]
  12. Löfdahl C. G., Dahlöf C., Westergren G., Olofsson B., Svedmyr N. Controlled-release metoprolol compared with atenolol in asthmatic patients: interaction with terbutaline. Eur J Clin Pharmacol. 1988;33 (Suppl):S25–S32. doi: 10.1007/BF00578409. [DOI] [PubMed] [Google Scholar]
  13. McDevitt D. G. The assessment of beta-adrenoceptor blocking drugs in man. Br J Clin Pharmacol. 1977 Aug;4(4):413–425. doi: 10.1111/j.1365-2125.1977.tb00756.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. McInnes G. T., Brodie M. J. Concentration-effect relationships for oxprenolol in patients with essential hypertension. Br J Clin Pharmacol. 1988 May;25(5):539–545. doi: 10.1111/j.1365-2125.1988.tb03343.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. McInnes G. T., Brodie M. J. Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension. Eur J Clin Pharmacol. 1988;34(6):605–611. doi: 10.1007/BF00615225. [DOI] [PubMed] [Google Scholar]
  16. Racine-Poon A., Moppert J. Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis. Br J Clin Pharmacol. 1985;19 (Suppl 2):143S–149S. doi: 10.1111/j.1365-2125.1985.tb02755.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Serlin M. J., Orme M. L., MacIver M., Green G. J., Sibeon R. G., Breckenridge A. M. The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension. Br J Clin Pharmacol. 1983 May;15(5):519–527. doi: 10.1111/j.1365-2125.1983.tb02085.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Theeuwes F., Swanson D. R., Guittard G., Ayer A., Khanna S. Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration. Br J Clin Pharmacol. 1985;19 (Suppl 2):69S–76S. doi: 10.1111/j.1365-2125.1985.tb02745.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Warrington S. J., Barclay S. P., John V. A., Shotton P. A., Good W. Comparison of single-dose pharmacokinetic and pharmacodynamic properties of two metoprolol Oros systems with different initial zero-order release rates. Br J Clin Pharmacol. 1985;19 (Suppl 2):225S–230S. doi: 10.1111/j.1365-2125.1985.tb02767.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Woods K. L., Jack D. B., Kendall M. J., Halsey A., O'Donnell M. L., Warrington S. J., John V. A. A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers. Br J Clin Pharmacol. 1985;19 (Suppl 2):177S–184S. doi: 10.1111/j.1365-2125.1985.tb02759.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. van Steveninck A. L., Schoemaker H. C., Pieters M. S., Kroon R., Breimer D. D., Cohen A. F. A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther. 1991 Aug;50(2):172–180. doi: 10.1038/clpt.1991.122. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES